Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13049-13059

  Chen, Huiming ^a,b   Gao, Shijuan ^a   Li, Jiandong ^a   Liu, Dong ^a   Sheng, Chunjie ^a   Yao, Chen ^a,b   Jiang, Wei ^a   Wu, Jiaoxiang ^a,b   Chen, Shuai ^a,c   Huang, Wenlin ^a,c,d  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b ANHUI UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d Guangzhou Double Bioproduct Inc   (China)

Author keywords

Apoptosis; Cell cycle; Cell migration; Epigenetic cancer therapy; Surface plasmon resonance

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; EPIGALLOCATECHIN GALLATE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; WEDELOLACTONE; COUMARIN DERIVATIVE; EED PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTIC LEUKEMIA; MYELOID LEUKEMIA CELL LINE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; HEK293 CELL LINE; HEP-G2 CELL LINE; K-562 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; COUMARINS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HEK293 CELLS; HEP G2 CELLS; HUMANS; K562 CELLS; LIVER NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84931026048     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3790     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. Dawson MA and Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150:12-27.
3. Aumann S and Abdel-Wahab O. Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochemical and biophysical research communications. 2014.
4. Filion GJ, van Bemmel JG, Braunschweig U, Talhout W, Kind J, Ward LD, Brugman W, de Castro IJ, Kerkhoven RM, Bussemaker HJ and van Steensel B. Systematic protein location mapping reveals five principal chromatin types in Drosophila cells. Cell. 2010; 143:212-224.
5. Schwartz YB and Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature reviews Genetics. 2007; 8:9-22.
6. Schwartz YB, Kahn TG, Nix DA, Li XY, Bourgon R, Biggin M and Pirrotta V. Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nature genetics. 2006; 38:700-705.
7. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B and Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003; 300:131-135.
8. Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, Zhang Y and Feil R. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nature genetics. 2004; 36:1296-1300.
9. Aloia L, Di Stefano B and Di Croce L. Polycomb complexes in stem cells and embryonic development. Development. 2013; 140:2525-2534.
10. Martinez AM and Cavalli G. The role of polycomb group proteins in cell cycle regulation during development. Cell cycle. 2006; 5:1189-1197.
11. Cao R, Tsukada Y and Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Molecular cell. 2005; 20:845-854.
12. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang YL, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464:1071-1148.
13. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie HF, Orkin SH and Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:5028-5033.
14. Gao SB, Xu B, Ding LH, Zheng QL, Zhang L, Zheng QF, Li SH, Feng ZJ, Wei J, Yin ZY, Hua X and Jin GH. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma. Journal of hepatology. 2014.
15. Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J and Cheng J. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013; 4:2532-2549.
16. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & development. 2007; 21:1050-1063.
17. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature chemical biology. 2012; 8:890-896.
18. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492:108-112.
19. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298:1039-1043.
20. Han Z, Xing X, Hu M, Zhang Y, Liu P and Chai J. Structural basis of EZH2 recognition by EED. Structure. 2007; 15:1306-1315.
21. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD and Orkin SH. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nature chemical biology. 2013; 9:643-650.
22. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE and Eckert RL. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis. 2011; 32:1525-1532.
23. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu YS and Nicolaides NC. Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes. Oncotarget. 2011; 2:1227-1243.
24. Chen H, Tu SW and Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. The Journal of biological chemistry. 2005; 280:22437-22444.
25. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S and Chinnaiyan AM. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer cell. 2007; 12:419-431.
26. Rayess H, Wang MB and Srivatsan ES. Cellular senescence and tumor suppressor gene p16. International journal of cancer Journal international du cancer. 2012; 130:1715-1725.
27. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:21360-21365.
28. Chinaranagari S, Sharma P and Chaudhary J. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget. 2014; 5:7172-7182.
29. Pasini D, Bracken AP and Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell cycle. 2004; 3:396-400.
30. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P and Bhalla K. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Molecular cancer therapeutics. 2006; 5:3096-3104.
31. Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, Lipkin SM and Gudas LJ. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Experimental cell research. 2013; 319:1463-1470.
32. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, Tan PH, Bay BH, Itahana K and Tan P. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:4201-4212.
33. Lin YH, Lee CC, Chang FR, Chang WH, Wu YC and Chang JG. 16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells. Life sciences. 2011; 89:886-895.
34. Chiang CW, Huang Y, Leong KW, Chen LC, Chen HC, Chen SJ and Chou CK. PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. Journal of biomedical science. 2010; 17:35.
35. Newman DJ, Cragg GM, Holbeck S and Sausville EA. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Current cancer drug targets. 2002; 2:279-308.
36. Kleer CG, Cao Q, Varambally S, Shen RL, Ota L, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:11606-11611.
37. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF and Xie D. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010; 31:1576-1583.
38. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S and Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008; 27:7274-7284.
39. Benes P, Knopfova L, Trcka F, Nemajerova A, Pinheiro D, Soucek K, Fojta M and Smarda J. Inhibition of topoisomerase IIalpha: novel function of wedelolactone. Cancer letters. 2011; 303:29-38.
40. Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, Hsieh SC and Hsiao PW. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:5435-5444.
41. Sun W and Yang J. Functional mechanisms for human tumor suppressors. Journal of Cancer. 2010; 1:136-140.